Preparing a Biotechnology Company for Its First Commercial Launch
Moving from an R&D organization to a commercial company changes almost everything.
The First Launch Transition
Launching a first therapy is one of the most important transitions an emerging biotechnology company will ever make.
Until this stage, much of the organization has been built around discovering, developing and securing approval for an innovative therapy. Commercialization introduces a different operating environment.
Patients must be identified. Physicians must understand where the therapy fits. Payers must determine coverage. Distribution must function. Patient-support systems must operate. Commercial teams must be recruited. Medical, commercial, access, legal, regulatory, finance, supply chain and executive leadership must begin operating as an integrated launch organization.
For a company doing this for the first time, there is little institutional launch experience to rely upon. That is where experienced commercial judgment becomes particularly valuable.
The First Launch Is an Organizational Transformation
A first launch should not be treated as a marketing project. It is a company transformation.
Leadership must answer questions such as:
- What capabilities must exist before launch?
- Which capabilities should be internal?
- Which can be outsourced?
- When should each commercial function be established?
- How large should the field organization become?
- What does the patient access model require?
- Which Centers of Excellence will influence adoption?
- How should Medical Affairs and Commercial coordinate?
- What evidence is still missing?
- What assumptions could undermine the launch?
- How should progress be communicated to the board?
These decisions should be sequenced rather than addressed simultaneously at the end of development.
Building the Launch Roadmap
PharmaKonsult helps leadership translate the commercialization challenge into an integrated roadmap covering market understanding, access readiness, organization and launch governance.
Market Understanding
Patient journey, diagnosis, referral, treatment patterns, physician segmentation, institutional dynamics, Centers of Excellence and competitive landscape.
Access Readiness
Payer considerations, reimbursement barriers, specialty pharmacy, distribution, patient support, prior authorization and health economic evidence.
Organization
Executive commercial leadership, Medical Affairs, Market Access, commercial operations, marketing, sales, patient services, analytics and training.
Launch Governance
Milestones, owners, dependencies, risk management, cross-functional meetings, escalation process and executive oversight.
Right-Sizing the Commercial Organization
More people do not automatically produce a better launch. Emerging biotechnology companies must balance commercial ambition with financial discipline.
The appropriate commercial model should reflect number of patients, treating physicians, geography, institutional concentration, treatment complexity, reimbursement, patient support requirements, competitive intensity and expected adoption pathway.
Rare disease and specialty markets frequently require highly focused commercial models rather than traditional large sales organizations. See also Commercial Organization Strategy and Launch Excellence.
Independent Commercial Perspective
Internal teams are understandably close to the asset. Independent commercial review can help leadership challenge forecasts, timelines, hiring plans, market assumptions, adoption expectations, budget priorities, organizational structure, access strategy and launch dependencies.
The purpose is not criticism. The purpose is to identify risk while leadership still has time to respond.
A successful first launch begins when leadership recognizes that commercialization is a company-wide capability that must develop alongside the therapy.
Preparing for your first commercial launch?
Let's discuss where your organization is today, what must exist before launch and where commercial risk may still remain.
